INTERVENTION 1:	Intervention	0
Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine	Intervention	1
cyclophosphamide	CHEBI:4026	13-29
breast	UBERON:0000310	37-43
vaccine	VO:0000001	50-57
All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine	Intervention	2
cyclophosphamide	CHEBI:4026	41-57
breast	UBERON:0000310	65-71
vaccine	VO:0000001	78-85
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed adenocarcinoma of the breast, meeting one of the following criteria:	Eligibility	1
adenocarcinoma	DOID:299	25-39
breast	UBERON:0000310	47-53
Metastatic disease	Eligibility	2
disease	DOID:4,OGMS:0000031	11-18
High-risk disease, defined as early-stage disease with pathologic involvement of locoregional lymph nodes	Eligibility	3
disease	DOID:4,OGMS:0000031	10-17
disease	DOID:4,OGMS:0000031	42-49
lymph	UBERON:0002391	94-99
Patients who are/will be receiving standard adjuvant trastuzumab [Herceptin®] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy	Eligibility	4
adjuvant	CHEBI:60809	44-52
disease	DOID:4,OGMS:0000031	92-99
No clinical or radiographical evidence of active disease	Eligibility	5
active	PATO:0002354	42-48
disease	DOID:4,OGMS:0000031	49-56
Not eligible for therapy of known curative potential for metastatic breast cancer	Eligibility	6
breast cancer	DOID:1612	68-81
HER2/neu-overexpressing disease, defined as HER2/neu positive by IHC 3+ staining or by FISH+ amplification	Eligibility	7
disease	DOID:4,OGMS:0000031	24-31
Stable CNS disease allowed provided it has been adequately treated and is not under active treatment	Eligibility	8
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	11-18
active	PATO:0002354	84-90
Hormone receptor status not specified	Eligibility	9
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	10
patient	HADO:0000008,OAE:0001817	0-7
Menopausal status not specified	Eligibility	11
ECOG performance status 0-1	Eligibility	12
ANC > 1,000/mm^3	Eligibility	13
Platelet count > 100,000/mm^3	Eligibility	14
platelet count	CMO:0000029	0-14
Serum creatinine < 2.0 mg/dL	Eligibility	15
creatinine	CHEBI:16737	6-16
Serum bilirubin  2.0 mg/dL (unless elevation is due to known Gilbert's syndrome)	Eligibility	16
syndrome	DOID:225	71-79
AST/ALT  2 times upper limit of normal (ULN)	Eligibility	17
Alkaline phosphatase  5 times ULN	Eligibility	18
phosphatase	GO:0016791,BAO:0000295	9-20
Not pregnant or nursing	Eligibility	19
Negative pregnancy test	Eligibility	20
Fertile patients must use effective contraception	Eligibility	21
Cardiac ejection fraction normal by MUGA OR  45% by ECHO	Eligibility	22
ejection fraction	CMO:0000180	8-25
No other malignancies within the past 5 years, except for carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer	Eligibility	23
carcinoma	HP:0030731,DOID:305	58-67
skin cancer	DOID:4159	115-126
cancer	DOID:162	120-126
cancer	DOID:162	151-157
No prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:	Eligibility	24
active	PATO:0002354	22-28
autoimmune disease	DOID:417	29-47
Inflammatory bowel disease	Eligibility	25
inflammatory bowel disease	DOID:0050589	0-26
Systemic vasculitis	Eligibility	26
vasculitis	HP:0002633,DOID:865	9-19
Scleroderma	Eligibility	27
scleroderma	HP:0100324,DOID:419,DOID:418	0-11
Psoriasis	Eligibility	28
psoriasis	DOID:8893	0-9
Multiple sclerosis	Eligibility	29
multiple sclerosis	DOID:2377	0-18
Hemolytic anemia or immune-mediated thrombocytopenia	Eligibility	30
hemolytic anemia	HP:0001878,DOID:583	0-16
thrombocytopenia	HP:0001873,DOID:1588	36-52
Rheumatoid arthritis	Eligibility	31
rheumatoid arthritis	HP:0001370,DOID:7148	0-20
Systemic lupus erythematosus	Eligibility	32
systemic lupus erythematosus	HP:0002725,DOID:9074	0-28
Sjögren syndrome	Eligibility	33
syndrome	DOID:225	8-16
Sarcoidosis	Eligibility	34
sarcoidosis	DOID:11335	0-11
Other rheumatologic disease	Eligibility	35
disease	DOID:4,OGMS:0000031	20-27
No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest	Eligibility	36
lung disease	DOID:850	25-37
dyspnea	HP:0002094	95-102
HIV-negative	Eligibility	37
No evidence of active acute or chronic infection	Eligibility	38
active	PATO:0002354	15-21
acute	HP:0011009,PATO:0000389	22-27
chronic infection	HP:0031035	31-48
No uncontrolled medical problems	Eligibility	39
No active major medical or psychosocial problems that could be complicated by study participation	Eligibility	40
active	PATO:0002354	3-9
No corn allergy	Eligibility	41
allergy	HP:0012393	8-15
No known severe hypersensitivity to trastuzumab (except for mild to moderate infusion reactions that are easily managed and do not recur) NOTE: *Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed	Eligibility	42
severe	HP:0012828	9-15
hypersensitivity	GO:0002524,DOID:1205	16-32
mild	HP:0012825	60-64
moderate	HP:0012826	68-76
asthma	HP:0002099,DOID:2841	145-151
chronic obstructive pulmonary disease	DOID:3083	155-192
PRIOR CONCURRENT THERAPY:	Eligibility	43
Any number of prior chemotherapy regimens for metastatic breast cancer allowed	Eligibility	44
breast cancer	DOID:1612	57-70
Prior or concurrent trastuzumab in the adjuvant or metastatic setting allowed	Eligibility	45
adjuvant	CHEBI:60809	39-47
More than 28 days since prior and no concurrent systemic oral steroids	Eligibility	46
Topical, ocular, or nasal steroids allowed	Eligibility	47
More than 28 days since prior and no concurrent chemotherapy, radiotherapy, or biologic therapy (except trastuzumab)	Eligibility	48
radiotherapy	OAE:0000235	62-74
More than 28 days since prior and no concurrent participation in another investigational clinical trial involving a new drug	Eligibility	49
drug	CHEBI:23888	120-124
Concurrent endocrine therapy or bisphosphonates allowed	Eligibility	50
Outcome Measurement:	Results	0
Safety as Assessed by Number of Participants Experiencing Toxicity	Results	1
Safety as assessed by number of participants who experienced drug-related local and systemic toxicity, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0) in response to CY-modulated immunization with a novel breast cancer vaccine in the setting of weekly Trastuzumab therapy.	Results	2
cancer	DOID:162	126-132
cancer	DOID:162	268-274
breast cancer	DOID:1612	261-274
vaccine	VO:0000001	275-282
Time frame: 4 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine	Results	5
cyclophosphamide	CHEBI:4026	30-46
breast	UBERON:0000310	54-60
vaccine	VO:0000001	67-74
Arm/Group Description: All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine	Results	6
cyclophosphamide	CHEBI:4026	64-80
breast	UBERON:0000310	88-94
vaccine	VO:0000001	101-108
Overall Number of Participants Analyzed: 20	Results	7
Measure Type: Count of Participants	Results	8
Unit of Measure: Participants  Patients with drug-related toxicity: 20 100.0%	Results	9
Patients with grade 3+ drug-related toxicity: 0   0.0%	Results	10
Patients with serious drug-related toxicity: 0   0.0%	Results	11
Adverse Events 1:	Adverse Events	0
Total: 0/20 (0.00%)	Adverse Events	1
